MedKoo Cat#: 318555 | Name: Practolol
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Practolol is a selective beta blocker that has been used in the emergency treatment of cardiac arrhythmias. Practolol is no longer used as it is highly toxic despite the similarity of its chemical formula to propranolol.

Chemical Structure

Practolol
Practolol
CAS#6673-35-4 (freebase)

Theoretical Analysis

MedKoo Cat#: 318555

Name: Practolol

CAS#: 6673-35-4 (freebase)

Chemical Formula: C14H22N2O3

Exact Mass: 266.1630

Molecular Weight: 266.34

Elemental Analysis: C, 63.13; H, 8.33; N, 10.52; O, 18.02

Price and Availability

Size Price Availability Quantity
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,150.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 5,250.00 2 Weeks
5g USD 7,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
6673-35-4 (freebase) 6996-43-6 (HCl)
Synonym
Practolol; Dalzic; Eraldin; ICI 50172; ICI-50172; ICI50172; Eralzdin; Teranol;
IUPAC/Chemical Name
N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
InChi Key
DURULFYMVIFBIR-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
SMILES Code
CC(C)NCC(COC1=CC=C(C=C1)NC(=O)C)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Practolol is a potent and selective β1-adrenergic receptor antagonist.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMSO 100.0 375.46
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 266.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Carbonnelle E, Josserand V, Riou LM, Ormezzano O, Broisat A, Perret P, Barone-Rochette G, Fagret D, Ghezzi C. Preclinical characterization of a novel radiolabeled analog of practolol for the molecular imaging of myocardial β-adrenoceptor density. J Nucl Cardiol. 2014 Oct;21(5):984-92. doi: 10.1007/s12350-014-9913-5. Epub 2014 May 30. PubMed PMID: 24875578. 2: Mann RD. An instructive example of a long-latency adverse drug reaction--sclerosing peritonitis due to practolol. Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1211-6. PubMed PMID: 17853493. 3: Abraham J, Davis C. Testing times: the emergence of the practolol disaster and its challenge to British drug regulation in the modern period. Soc Hist Med. 2006 Apr;19(1):127-47. PubMed PMID: 17153164. 4: Mann RD. A ranked presentation of the MHRA/CSM (Medicines & Health Care Regulatory Agency/Committee on Safety of Medicines) Drug Analysis Print (DAP) data on practolol. Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):705-10. PubMed PMID: 16088980. 5: Tong A, Wu Y, Li L. [Room temperature phosphorimetric determination of practolol with dansyl chloride labeling]. Guang Pu Xue Yu Guang Pu Fen Xi. 1998 Feb;18(1):38-42. Chinese. PubMed PMID: 15810329. 6: Scarfe GB, Lindon JC, Nicholson JK, Martin P, Wright B, Taylor S, Lenz E, Wilson ID. Investigation of the metabolism of 14C/13C-practolol in rat using directly coupled radio-HPLC-NMR-MS. Xenobiotica. 2000 Jul;30(7):717-29. PubMed PMID: 10963062. 7: Varga E, Szöllösi J, Antal K, Kovács P, Szabó JZ. Nonspecific membrane effects of CH-103: hydrophobicity, surface activity and membrane fluidity studies in comparison with propranolol and practolol. Pharmazie. 1999 May;54(5):380-4. PubMed PMID: 10368833. 8: Leftheris K, Goodman M. Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives. J Med Chem. 1990 Jan;33(1):216-23. PubMed PMID: 1967313. 9: Sim E, Stanley L, Gill EW, Jones A. Metabolites of procainamide and practolol inhibit complement components C3 and C4. Biochem J. 1988 Apr 15;251(2):323-6. PubMed PMID: 2456755; PubMed Central PMCID: PMC1149005. 10: Elliott GR, Amos HE, Miller K, Bridges JW. Practolol inhibits human skin fibroblast cell mat hydroxyproline accumulation. Agents Actions. 1987 Oct;22(1-2):106-13. PubMed PMID: 3687592. 11: Khan MM, Marr-Leisy D, Rosenkranz R, Hoffman BB, Verlander MS, Goodman M, Melmon KL. In vitro pharmacologic activity of congener derivatives and model conjugates of propranolol and practolol. Biochem Pharmacol. 1987 Jul 1;36(13):2175-82. PubMed PMID: 3038116. 12: Green KG. Falsely favourable early prognosis for continuing smokers following recovery from acute myocardial infarction. Information from the multi-centre practolol trial. Br J Clin Pract. 1987 Jun;41(6):785-8. PubMed PMID: 3446275. 13: Rosenbaum SE, Lindup WE, Orton TC. Practolol: aspects of its metabolism and ocular binding in the hamster. Xenobiotica. 1986 Jun;16(6):567-73. PubMed PMID: 3751112. 14: Brandt R, Seppälä E, Nowak J, Vapaatalo H. Effect of propranolol, practolol and atenolol on human platelet thromboxane formation and plasma levels of prostaglandins 6-keto-F1 alpha and E2. Prostaglandins Leukot Med. 1984 Nov;16(2):191-203. PubMed PMID: 6597450. 15: Virtanen KS, Nieminen MS. Marked relief of acute exacerbation of congestive cardiomyopathy by intravenous practolol--report of a case. Eur Heart J. 1984 May;5(5):423-6. PubMed PMID: 6734653. 16: Berger G, Prenant C, Sastre J, Syrota A, Comar D. Synthesis of a beta-blocker for heart visualization: [11C]practolol. Int J Appl Radiat Isot. 1983 Nov;34(11):1556-7. PubMed PMID: 6139343. 17: Davy M, Lindenbaum A, Cohen Y, Wepierre J. Mechanism of the hypotensive action of practolol in the anesthetized rat. Arch Int Pharmacodyn Ther. 1983 Oct;265(2):283-92. PubMed PMID: 6651412. 18: Antonini G, Franconi F, Giotti A, Ledda F, Mantelli L, Stendardi I. Reoxygenation dysrhythmias in the isolated guinea-pig heart: sensitivity to prazosin, atenolol and practolol. Pharmacol Res Commun. 1983 Sep;15(8):751-63. PubMed PMID: 6634908. 19: Mehta AC, Calvert RT. High-performance liquid chromatographic determination of practolol in plasma. J Chromatogr. 1983 Aug 12;276(1):208-12. PubMed PMID: 6672015. 20: Maharaj RJ, Thompson M, Brock-Utne JG, Williamson R, Downing JW. Treatment of hypertension following endotracheal intubation. A study comparing the efficacy of labetalol, practolol and placebo. S Afr Med J. 1983 Apr 30;63(18):691-4. PubMed PMID: 6342168.